Published in Cancer Weekly, December 23rd, 2003
Using various analytical methods, EntreMed scientists designed and synthesized modifications of the structure of 2-methoxyestradiol (2ME2) to create NCEs with enhanced antitumor and antiangiogenic activities in in vitro models.
EntreMed President and Chief Operating...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.